Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 23294853

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2013 Feb
First author
Kellokumpu-Lehtinen PL

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2013 Feb;14(2):98-9. doi: 10.1016/S1470-2045(12)70579-X.
    note
    Source null
    related pmid
    23294852
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2013 Mar;10(3):123. doi: 10.1038/nrclinonc.2013.6.
    note
    Source null
    related pmid
    23337917
    relationship
    Comment in
  3. citation
    Nat Rev Urol. 2013 Mar;10(3):123. doi: 10.1038/nrurol.2013.12.
    note
    Source null
    related pmid
    23358518
    relationship
    Comment in

Authors and identifiers

  1. name
    Kellokumpu-Lehtinen PL
    type
    Author
  2. name
    Harmenberg U
    type
    Author
  3. name
    Joensuu T
    type
    Author
  4. name
    McDermott R
    type
    Author
  5. name
    Hervonen P
    type
    Author
  6. name
    Ginman C
    type
    Author
  7. name
    Luukkaa M
    type
    Author
  8. name
    Nyandoto P
    type
    Author
  9. name
    Hemminki A
    type
    Author
  10. name
    Nilsson S
    type
    Author
  11. name
    McCaffrey J
    type
    Author
  12. name
    Asola R
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kellokumpu-Lehtinen PL
    type
    Author
  2. name
    Harmenberg U
    type
    Author
  3. name
    Joensuu T
    type
    Author
  4. name
    McDermott R
    type
    Author
  5. name
    Hervonen P
    type
    Author
  6. name
    Ginman C
    type
    Author
  7. name
    Luukkaa M
    type
    Author
  8. name
    Nyandoto P
    type
    Author
  9. name
    Hemminki A
    type
    Author
  10. name
    Nilsson S
    type
    Author
  11. name
    McCaffrey J
    type
    Author
  12. name
    Asola R
    type
    Author
bibliography ids
  1. nci-bib-fa2da4ed24dc385e8d1882de
book metadata
content sha256
4d81d9b49dc17f7dfd3160a74780732c9c1bd8f0c10d898e8babd5f5bca6d96e
document type
citation
dois
  1. 10.1016/S1470-2045(12)70537-5
electronic publication date
display
2013 Jan 4
precision
day
year
2013
evidence scope
bibliographic_metadata_only
id
pubmed:23294853
immutable id
pubmed:23294853@4d81d9b49dc17f7dfd3160a74780732c9c1bd8f0c10d898e8babd5f5bca6d96e
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
117-24
volume
14
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2013 Feb;14(2):98-9. doi: 10.1016/S1470-2045(12)70579-X.
    note
    Source null
    related pmid
    23294852
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2013 Mar;10(3):123. doi: 10.1038/nrclinonc.2013.6.
    note
    Source null
    related pmid
    23337917
    relationship
    Comment in
  3. citation
    Nat Rev Urol. 2013 Mar;10(3):123. doi: 10.1038/nrurol.2013.12.
    note
    Source null
    related pmid
    23358518
    relationship
    Comment in
outcomes validated
false
pmid
23294853
provenance
batch id
99e85dbb34a1a3011c9a
provider
NCBI PubMed ESummary
record sha256
d45cbafd00bea1a1da246994cccee9d5091c27d8d24612566ccebd45700ed022
response sha256
1f4a46dcee9da36f8f58fe356dce3f44a1b3004f404e9fb0184f4e08aed4acf2
retrieved at
2026-09-09T23:46:52.860383+00:00
publication date
display
2013 Feb
precision
month
year
2013
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/23294853/
title
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Preserved source evidence · Not medical advice